- Home
- ALIT vs RIGL Comparison
ALIT vs RIGL Comparison
Compare ALIT & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALIT | RIGL |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 568.2M | 564.7M |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ALIT | RIGL |
|---|---|---|
| Price | $16.98 | $36.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $3.75 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 714.3K | 324.2K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 21.33% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | ★ $2,262,000,000.00 | $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.14 | $12.75 |
| P/E Ratio | ★ N/A | $86.48 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $0.48 | $21.81 |
| 52 Week High | $23.68 | $52.24 |
Technical Indicators
Market Signals| Indicator | ALIT | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 56.14 | 45.12 |
| Support Level | $1.12 | $33.93 |
| Resistance Level | $23.68 | $44.42 |
| Average True Range (ATR) | 1.71 | 1.72 |
| MACD | -0.90 | -0.59 |
| Stochastic Oscillator | 2.91 | 24.53 |
Price Performance
Historical ComparisonAbout ALIT Alight Inc.
Alight Inc is a technology-enabled services company delivering human capital management solutions to many complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth, and leave benefits) solutions, which currently operate under one reportable segment, Employer Solutions. The Employer Solutions segment is driven by the Alight Worklife platform, and includes integrated benefits administration, healthcare navigation, financial well-being, leave of absence management, and retiree healthcare. Geographically, the company generates the majority of its revenue from the United States.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.